SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kosan BioSciences -- KOSN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (753)11/21/2006 6:36:02 PM
From: VanBio   of 933
 
I agree, if you look at the major partnerships/acquisitions two out of the three are with major biotechs building their pipelines. Once the Hsp90 target is "sufficiently" validated many companies could potentially try and jump start their own programs by partnering with KOSN or other companies in the space. My hypothesis is that the smaller players are still taking more risky bets than big pharma, but I could be wrong.

Conforma: Biogen Idec (Conforma funded by Lilly, and I believe GSK Venture arms..)
Infinity: Medimmune
Novartis: Vernalis (Novartis has its own internal programs as well)

Major players with HSP90 inhibitor programs:
-Sanofi-Aventis
-Merck KgA
-Pfizer
-Abraxis
-Kyowa Hakko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News